EntreMed, Inc., a clinical-stage biopharmaceutical company, engages in the development of oncology and antiinflammatory drugs. The company’s clinical drug candidates include Panzem (2-methoxyestradiol), which is in Phase 2 clinical trials for cancer, as well as in preclinical development for rheumatoid arthritis; MKC-1, a cell cycle inhibitor, which is in Phase 2 clinical trials for cancer; and ENMD-1198, a tubulin binding agent that is in Phase 1 clinical trials. Its preclinical product pipeline include 2ME2 for rheumatoid arthritis; MKC-1693, an aurora kinase inhibitor; Tubulin inhibitors that comprise a family of compounds that bind to tubulin and disrupt microtubules...
read more
EK, Eastman Kodak Co.
** EK, in response to rumors circulating in the capital markets, reported that it is committed to meeting all of its obligations and has no intention of filing for bankruptcy.
EK helps consumers, businesses, and creative professionals unleash the power of images, information, and printing to enrich their lives.
More about EK at www.kodak.com
******************
ENMD, read more
EK, Eastman Kodak Co.
** EK, in response to rumors circulating in the capital markets, reported that it is committed to meeting all of its obligations and has no intention of filing for bankruptcy.
EK helps consumers, businesses, and creative professionals unleash the power of images, information, and printing to enrich their lives.
More about EK at www.kodak.com
******************
ENMD, read more
EK, Eastman Kodak Co.
** EK, in response to rumors circulating in the capital markets, reported that it is committed to meeting all of its obligations and has no intention of filing for bankruptcy.
EK helps consumers, businesses, and creative professionals unleash the power of images, information, and printing to enrich their lives.
More about EK at www.kodak.com
******************
ENMD, read more